Acumen Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Acumen Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than almost all Healthcare companies in United States.
- Tangible Net Worth Ratio: Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies. More tangible than 97% of Healthcare companies in United States.
- Tangible Assets Ratio: Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles. More tangible than 97% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
-1,958.5×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than almost all Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 0/3Sales and profit both fell in each of the last 3 years.
Less steady than 96% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-13.2×Operating cash was negative last year, while some debt falls due within a year.
Higher than 52% of Healthcare companies in United States.
Cash Cushion Ratio
+57%Cash, after subtracting all debt, equals 57% of its market value (net cash).
Higher than 79% of Healthcare companies in United States.
Tangible Assets Ratio
100%Of every $100 the company owns, $100 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 97% of Healthcare companies in United States.
Tangible Net Worth Ratio
100%Of every $100 of net worth, $100 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 97% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (11)
Acumen Pharmaceuticals, Inc. made a loss over the last year. Acumen Pharmaceuticals, Inc. owes $0.51 for every $1 it owns. Acumen Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAcumen Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
2.60The share price is 2.60 times Acumen Pharmaceuticals, Inc.'s book value per share, higher than 50% of Healthcare companies in United States.
Market cap
$149 MThe total market value of all of Acumen Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 61% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$57 MWhat Acumen Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.79Net worth divided by the number of shares. The share price of $2.06 is 2.6 times this, which is the P/B above.
Return on equity (ROE)
-120.5%Acumen Pharmaceuticals, Inc. lost 120.5% of its shareholders' money over the last year, lower than 76% of Healthcare companies in United States.
Owes vs Owns
0.51×Acumen Pharmaceuticals, Inc. owes $0.51 for every $1 it owns (moderate), higher than 56% of Healthcare companies in United States.
Dividend yield
NoneAcumen Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossAcumen Pharmaceuticals, Inc. made a loss in each of the last two years.
Interest cover
Not coveredAcumen Pharmaceuticals, Inc.'s operating profit did not cover its interest costs in the year to Dec 2025.
Cash vs debt
Net cashAcumen Pharmaceuticals, Inc. held $86 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Acumen Pharmaceuticals, Inc.: $149 M ÷ $57 M (30 Jun 2026) = 2.6.
What is Acumen Pharmaceuticals, Inc.'s return on equity?
Acumen Pharmaceuticals, Inc. lost 120.5% of its shareholders' money over the last year, lower than 76% of Healthcare companies in United States.
How much does Acumen Pharmaceuticals, Inc. owe compared with what it owns?
Acumen Pharmaceuticals, Inc. owes $0.51 for every $1 it owns (moderate), higher than 56% of Healthcare companies in United States.
Does Acumen Pharmaceuticals, Inc. pay a dividend?
No. Acumen Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.